DBV Technologies S.A. — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021. DBV is a clinical-stage biopharmaceutical company developing Viaskin, an epicutaneous immunotherapy platform. It reported no product sales; operating income primarily reflects a French research tax credit and collaboration income.
Financial performance and position
| Metric | Q1 2021 | Q1 2020 or prior period |
|---|---|---|
| Operating income | $2.9 million | $4.7 million, down 37.7% |
| Research and development expense | $22.2 million | $27.5 million, down 19.5% |
| Sales and marketing expense | $0.7 million | $7.3 million, down 90.0% |
| General and administrative expense | $9.7 million | $11.1 million, down 12.9% |
| Total operating expenses | $32.6 million | $45.9 million, down 29.1% |
| Net loss | $29.4 million | $40.9 million |
| Basic/diluted loss per share | $0.54 | $0.79 |
| Operating cash flow | $(36.2) million | $(49.7) million |
| Cash and cash equivalents, March 31 | $152.5 million | $196.4 million at Dec. 31, 2020 |
Cash declined by $43.9 million during the quarter, including a $7.9 million adverse foreign-exchange effect. Investing used $0.2 million; financing provided $0.4 million. No product gross margin or operating margin is meaningful given the absence of product sales and continued losses.
At March 31, total assets were $221.4 million, total liabilities $52.2 million, and shareholders’ equity $169.2 million. Financial debt was approximately $1.1 million ($0.7 million current and $0.4 million long-term); operating lease liabilities totaled approximately $12.8 million. Current assets were $159.8 million and current liabilities $38.8 million.
Material changes and operating developments
- Operating expenses fell $13.4 million year over year, primarily reflecting workforce reductions and cost controls under the 2020 restructuring plan. Average headcount declined from 311 to 121; the company reported 104 employees at March 31.
- Operating income decreased 37.7%, mainly because lower eligible R&D spending reduced the French research tax credit; collaboration income also declined.
- The FDA had issued a Complete Response Letter in August 2020 for the Viaskin Peanut BLA, citing patch adhesion/efficacy concerns, patch modifications, additional clinical data, a human-factor study, and additional manufacturing data. In January 2021, FDA feedback outlined a potential path forward, including allergen-uptake comparison and a recommended six-month safety and adhesion study. DBV planned to submit study protocols for FDA review.
- The EMA review of the Viaskin Peanut application for children ages 4–11 was ongoing; the first questions received in Q1 were described as expected, with no adhesion-related questions reported. Enrollment in Part B of the EPITOPE study for children ages 1–3 was completed during Q1.
Outlook, risks, and contingencies
- Management stated in the going-concern note that the March 31 cash balance was expected to fund operations for at least the next 12 months. The MD&A separately said cash was expected to support operations until the second half of 2022. DBV also said it intended to seek additional capital as it prepares for a potential launch and continues R&D.
- The global restructuring was expected to be fully implemented in the second half of 2021, with a planned reduction of more than 200 jobs. Restructuring liabilities were $4.3 million at March 31; $4.9 million was paid during the quarter. No restructuring expense was recorded in Q1.
- COVID-19 had reduced new clinical-trial enrollment and required protocol adaptations; DBV noted possible additional clinical and production costs. The filing also warns that pandemic-related market disruption could constrain or worsen terms for future financing.
- A U.S. securities class action seeks unspecified damages. The company disputes the allegations and stated it did not expect a material adverse effect on its financial position, results, or liquidity.
- Management reported disclosure controls and procedures were effective as of March 31 and no material change in internal control over financial reporting occurred during the quarter.
Key facts investors should verify
- Whether FDA-agreed study protocols, patch modification, uptake comparison, human-factor validation, and additional CMC requirements affect the timing, cost, or likelihood of a Viaskin Peanut resubmission and approval.
- Whether EMA review progresses as expected and what additional evidence or conditions regulators request.
- Cash burn, foreign-exchange effects, and the reconciliation between the stated “at least 12 months” runway and the MD&A estimate extending to the second half of 2022; also assess timing and terms of anticipated financing.
- Execution and remaining costs of the restructuring, and the effect of COVID-related trial delays on clinical timelines and collaboration income.